文献速递血管炎

巨细胞动脉炎随机对照试验中18F-FDG PET影像评估

18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.
PubMed 文献 · Arthritis Rheumatol · 2026-05-05

在一项国际多中心随机对照试验中,51例新发或复发性巨细胞动脉炎患者接受guselkumab或安慰剂联合逐渐减量糖皮质激素治疗,并于基线及疾病复发或第52周时行FDG-PET检查。基线FDG-PET显示55%患者为活动性血管炎,但与临床症状、急性期反应物或复发风险无关;FDG-PET活动与临床评估可能不一致。

要点

  • 基线FDG-PET活动与临床症状、急性期反应物及复发风险无关。
  • 年轻和女性与基线FDG-PET活动增加相关。
  • FDG-PET与临床评估可能不一致,影像学结局指标在治疗试验中应保持探索性。

核心结论

  • 血管FDG-PET活动可能与临床评估不一致,尤其在某些GCA患者亚组中。
  • 影像学为基础的结局指标在未来治疗试验中应保持探索性。

研究设计与样本

  • 国际多中心随机对照试验,新发或复发性GCA患者随机接受guselkumab或安慰剂联合逐渐减量糖皮质激素。
  • 基线访视随机化前及疾病复发或第52周访视时行FDG-PET,由两名阅片者判读为活动或不活动,并计算PET血管活动评分。

主要发现

  • 51例患者中28例(55%)基线FDG-PET判读为活动性血管炎。
  • 基线FDG-PET活动与临床症状、急性期反应物或复发风险无关。
  • 年轻年龄(70 vs 76岁;P=0.03)和女性(89% vs 48%,P<0.01)与FDG-PET活动增加显著相关。
  • 基线FDG-PET活动与不活动患者既往糖皮质激素剂量(中位780 mg)或疗程(中位23天)无差异。
  • 临床复发时21例中17例(81%)FDG-PET活动,第52周20例中14例(70%)活动;部分患者在所有时间点持续活动(n=21)或不活动(n=9),独立于临床评估。

关键数值与推荐

  • 基线FDG-PET活动性血管炎:28/51(55%)。
  • 临床复发时FDG-PET活动:17/21(81%)。
  • 第52周FDG-PET活动:14/20(70%)。
  • 年轻年龄与FDG-PET活动相关:70 vs 76岁,P=0.03。
  • 女性与FDG-PET活动相关:89% vs 48%,P<0.01。

临床怎么用

  • 在GCA治疗试验中,FDG-PET不宜作为主要疗效结局,应保持探索性。
  • 临床评估与FDG-PET可能不一致,解读影像结果需结合临床背景。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging to clinical- and laboratory-based assessments of disease activity in a randomized controlled trial (RCT) in giant cell arteritis (GCA). METHODS: Patients with new-onset or relapsing GCA were randomized to guselkumab or placebo plus tapered glucocorticoids in an international, multicenter RCT. FDG-PET was performed at the baseline visit before randomization and repeated at disease flare or the week-52 visit (clinical remission off glucocorticoids). FDG-PET scans were interpreted as active or inactive by two readers, and the PET Vascular Activity Score was calculated to quantify arterial FDG uptake. FDG-PET findings were compared to clinical assessment, acute phase reactants, and glucocorticoid use at each visit. RESULTS: Baseline FDG-PET scans were interpreted as active vasculitis in 28 (55%) of 51 patients. FDG-PET activity at enrollment was not associated with clinical symptoms, acute phase reactants, or risk of flare. Younger age (70 vs 76 years; P = 0.03) and female sex (89% vs 48%, P < 0.01) were significantly associated with increased FDG-PET activity. There were no differences in prior glucocorticoid dose (median 780 mg) or duration (median 23 days) between patients with baseline active versus inactive FDG-PET scans. FDG-PET scans were active in 17 of 21 (81%) patients during clinical flare and in 14 of 20 (70%) patients at week 52. Subsets of patients had persistently active (n = 21) or inactive (n = 9) PET scans at all time points, independent of clinical assessment. CONCLUSION: Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA. Imaging-based outcome measures should remain exploratory in future therapeutic trials.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Quinn KA, Tan S, Verdijk P, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis. Arthritis Rheumatol. 2026. PMID: 41940456. doi:10.1002/art.70166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。